Stammdaten
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Unternehmen & Branche
| Name | Sensus Healthcare, Inc. |
|---|---|
| Ticker | SRTS |
| CIK | 0001494891 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 64,4 Mio. USD |
| Beta | 1,28 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 27,482,000 | -7,719,000 | -0.47 | 53,039,000 | 48,098,000 |
| 2025-09-30 | 10-Q | 6,884,000 | -943,000 | -0.06 | 58,295,000 | 51,194,000 |
| 2025-06-30 | 10-Q | 7,315,000 | -1,037,000 | -0.06 | 58,852,000 | 52,064,000 |
| 2025-03-31 | 10-Q | 8,344,000 | -2,572,000 | -0.16 | 60,210,000 | 53,034,000 |
| 2024-12-31 | 10-K | 41,807,000 | 6,647,000 | 0.41 | 62,165,000 | 55,827,000 |
| 2024-09-30 | 10-Q | 8,839,000 | 1,215,000 | 0.07 | 59,858,000 | 54,131,000 |
| 2024-06-30 | 10-Q | 9,239,000 | 1,612,000 | 0.10 | 58,163,000 | 52,901,000 |
| 2024-03-31 | 10-Q | 10,663,000 | 2,274,000 | 0.14 | 57,273,000 | 51,207,000 |
| 2023-12-31 | 10-K | 24,405,000 | 485,000 | 0.03 | 53,710,000 | 48,842,000 |
| 2023-09-30 | 10-Q | 3,898,000 | -1,451,000 | -0.09 | 50,546,000 | 44,587,000 |
| 2023-06-30 | 10-Q | 4,527,000 | -380,000 | -0.02 | 52,017,000 | 46,010,000 |
| 2023-03-31 | 10-Q | 3,414,000 | -1,894,000 | -0.12 | 53,398,000 | 46,324,000 |
| 2022-12-31 | 10-K | 44,532,000 | 24,244,000 | 1.46 | 56,735,000 | 48,069,000 |
| 2022-09-30 | 10-Q | 9,010,000 | 1,829,000 | 0.11 | 54,759,000 | 47,124,000 |
| 2022-06-30 | 10-Q | 12,080,000 | 3,524,000 | 0.21 | 56,349,000 | 45,045,000 |
| 2022-03-31 | 10-Q | 10,338,000 | 16,062,000 | 0.97 | 53,929,000 | 42,458,000 |
| 2021-12-31 | 10-K | 27,042,000 | 4,119,000 | 0.25 | 32,240,000 | 26,015,000 |
| 2021-09-30 | 10-Q | 5,525,000 | 195,000 | 0.01 | 25,626,000 | 20,607,000 |
| 2021-06-30 | 10-Q | 5,422,000 | -279,000 | -0.02 | 26,362,000 | 20,215,000 |
| 2021-03-31 | 10-Q | 3,070,000 | -1,115,000 | -0.07 | 26,482,000 | 20,435,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | Sachetta Eric | Director | Open Market Purchase | 2,000 | 3.81 | 7,620.00 | +53,1% | |
| 2025-11-21 | Sachetta Eric | Director | Open Market Purchase | 7,000 | 3.93 | 27,510.00 | +191,6% | |
| 2025-11-18 | Sardano Joseph C | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Purchase | 25,000 | 4.03 | 100,750.00 | +701,8% | |
| 2025-11-18 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 1,000 | 3.80 | 3,800.00 | +26,5% | |
| 2025-11-13 | Sachetta Eric | Director | Open Market Purchase | 2,500 | 4.50 | 11,250.00 | +78,4% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 766 | 4.27 | 3,270.82 | +22,8% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 1,000 | 4.26 | 4,260.00 | +29,7% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 1,000 | 4.26 | 4,260.00 | +29,7% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 234 | 4.24 | 992.16 | +6,9% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 766 | 4.27 | 3,270.82 | +22,8% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 1,000 | 4.26 | 4,260.00 | +29,7% | |
| 2025-11-11 | Sardano Michael | Director, Officer, PRESIDENT AND GENERAL COUNSEL | Open Market Purchase | 234 | 4.34 | 1,015.56 | +7,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.